PCM
NBSE

Prelude Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Prelude Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,550
Closed -$7K – 1583
2024
Q1 		$7K Hold
15,550
– – ﹤0.01% 1279
2023
Q4 		$11.5K Hold
15,550
– – ﹤0.01% 1096
2023
Q3 		$13.5K Hold
15,550
– – ﹤0.01% 1074
2023
Q2 		$29.1K Hold
15,550
– – ﹤0.01% 1000
2023
Q1 		$57.5K Hold
15,550
– – ﹤0.01% 995
2022
Q4 		$59.2K Hold
15,550
– – ﹤0.01% 1121
2022
Q3 		$123K Hold
15,550
– – ﹤0.01% 1143
2022
Q2 		$327K Hold
15,550
– – 0.01% 1023
2022
Q1 		$585K Hold
15,550
– – 0.02% 796
2021
Q4 		$874K Hold
15,550
– – 0.02% 685
2021
Q3 		$1.12M Hold
15,550
– – 0.03% 516
2021
Q2 		$1.49M Hold
15,550
– – 0.04% 418
2021
Q1 		$2.3M Hold
15,550
– – 0.06% 296
2020
Q4 		$2.17M Buy
+15,550
New +$2.52M 0.06% 275
2017
Q4 		– Sell
-3
Closed -$1K – 1790
2017
Q3 		$1K Buy
+3
New +$819 ﹤0.01% 1571

Other funds holding NBSE

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Prelude Capital Management's NBSE Position: Q2 2024 in Review

Prelude Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 15,550 shares — an estimated $7K sold.

Prelude Capital Management first reported a position in NBSE in Q3 2017 and held it in 15 quarters. The position peaked at $2.3M in Q1 2021. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

  • Prelude Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 15,550 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $7K.
  • Prelude Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2017 and held it in 15 quarters.
  • Prelude Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.3M in Q1 2021.
  • 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.